We are live on ! Find out more
PHIO icon

Phio Pharmaceuticals
PHIO

11 hedge funds and large institutions have $117K invested in Phio Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

31% more capital inflows, than outflows

Capital inflows: $49.8K | Capital outflows: $38.1K

10% more funds holding

Funds holding: 10 → 11 (+1)

0.53% less ownership

Funds ownership: 7.41% → 6.89% (-0.53%)

Holders
11
Holders Change
+1
Holders Change %
+10%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
3
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$20.4K
2
Citadel Advisors
Citadel Advisors
Florida
+$15.8K
3
Two Sigma Securities
Two Sigma Securities
New York
+$9.05K
4
Cetera Investment Advisers
Cetera Investment Advisers
Illinois
+$3.63K
5
UBS Group
UBS Group
Switzerland
+$791

Top Sellers

Rank Fund Capital Flow
1
Virtu Financial
Virtu Financial
New York
-$21K
2
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$17.1K
3
Wells Fargo
Wells Fargo
California
-$13

PHIO Hedge Fund Activity: Q2 2024 in Review

11 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q2 2024, worth a combined $117K — down 7.8% from $127K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new PHIO positions and 3 closed out — a net gain of 2 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $20.4K. The largest seller was Virtu Financial, exiting entirely with an estimated $21K sold.

  • 11 institutional investors held Phio Pharmaceuticals (PHIO) as of Q2 2024, up from 10 in Q1 2024.
  • Funds reported $117K of Phio Pharmaceuticals stock for Q2 2024, down 7.8% quarter-over-quarter.
  • 5 funds opened new Phio Pharmaceuticals positions in Q2 2024 and 3 closed out, a net change of +2 holders.
  • The largest Phio Pharmaceuticals buyer in Q2 2024 was Geode Capital Management, an estimated $20.4K added.
  • The largest Phio Pharmaceuticals seller in Q2 2024 was Virtu Financial, an estimated $21K sold.

Based on aggregated 13F filings for Q2 2024.